Cargando…
Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting
T cell immunoglobulin domain and mucin domain-3 (TIM-3) is an important immune checkpoint (IC) protein in cancer immunosuppression that is considered a novel target for immunotherapy. Moreover, TIM-3, an immuno-myeloid regulator, is highly expressed on the cells of several solid tumors and myeloid l...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357734/ https://www.ncbi.nlm.nih.gov/pubmed/37468979 http://dx.doi.org/10.1186/s40164-023-00421-2 |